clofibrate has been researched along with Hyperlipoproteinemia in 81 studies
angiokapsul: contains clofibrate & insoitolnicotinate
| Excerpt | Relevance | Reference |
|---|---|---|
| "The long term effect of clofibrate treatment on the carbohydrate and lipid metabolisms and on insulin secretion was studied in subjects with primary hyperlipoproteinemia and impaired glucose tolerance." | 7.66 | Effects of clofibrate therapy on glucose tolerance, insulin secretion and serum lipids in subjects with hyperlipoproteinemia and impaired glucose tolerance. A follow-up study over a five-year period. ( Bruns, W; Ratzmann, KP; Ratzmann, ML; Rjasanowski, I, 1983) |
| "The effect of a combination of clofibrate and inositol nicotinate (Liporeduct forte, Liporeduct) on lipids and lipoproteins in 20 patients with primary hyperlipoproteinemia (10 type IIa, 7 type IV and 3 tyV) was investigated over a period of 16 weeks." | 7.66 | [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V]. ( Ditschuneit, H; Hutt, V; Klör, HU; Wechsler, JG, 1983) |
| "The effect of long-term treatment over 40 weeks with Bezafibrate on lipids and lipoproteins was investigated in 27 patients with primary hyperlipoproteinemias (hlp) (12 patients with hlp type IV, 7 patients with type IIb, 3 patients with type IIa, 4 patients with type V and 1 patient with type III)." | 7.66 | [Bezafibrate in primary hyperlipidemias (author's transl)]. ( Bode, G; Ditschuneit, H; Hutt, V; Klör, HU; Wechsler, JG, 1982) |
| "Pirozadil and alufibrate are compared by a single-blind study over two groups 20 patients with primary hyperlipoproteinemia." | 7.66 | [Single-blind study of the efficacy of pirozadil versus alufibrate in the treatment of primary hyperlipoproteinemias]. ( Azanza Perea, JR; Honorato Pérez, J, 1982) |
| "Clofibrate has cholesterol- and triglyceride-lowering effect." | 6.39 | [Clofibrate treatment of hyperlipoproteinemia]. ( Midorikawa, H; Oikawa, S, 1994) |
| " In type IIa etofylline clofibrate shows a good effect on total cholesterol and on the cholesterol fractions, both with regard to the collective treated and to the low dosage of 750 mg/d etofylline clofibrate compared to the usual dosage of 1500 mg clofibrate." | 5.26 | [On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)]. ( Hausmann, L; Mühlfellner, G; Mühlfellner, O; Schneider, J; Schubotz, R, 1980) |
| "A total of 98 patients selected and classified into type IIa and IIb hyperlipoproteinemia according to Fredrickson and Lees (1965) were pre-treated for 6 months with a commercially available combination product (containing clofibrate and nicotinic acid)." | 5.05 | [Therapy of lipoproteinemia. Comparison between Lipo-Merz retard and a commercial combination drug]. ( Steger, W, 1980) |
| "The long term effect of clofibrate treatment on the carbohydrate and lipid metabolisms and on insulin secretion was studied in subjects with primary hyperlipoproteinemia and impaired glucose tolerance." | 3.66 | Effects of clofibrate therapy on glucose tolerance, insulin secretion and serum lipids in subjects with hyperlipoproteinemia and impaired glucose tolerance. A follow-up study over a five-year period. ( Bruns, W; Ratzmann, KP; Ratzmann, ML; Rjasanowski, I, 1983) |
| "The effect of a combination of clofibrate and inositol nicotinate (Liporeduct forte, Liporeduct) on lipids and lipoproteins in 20 patients with primary hyperlipoproteinemia (10 type IIa, 7 type IV and 3 tyV) was investigated over a period of 16 weeks." | 3.66 | [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V]. ( Ditschuneit, H; Hutt, V; Klör, HU; Wechsler, JG, 1983) |
| "The effect of long-term treatment over 40 weeks with Bezafibrate on lipids and lipoproteins was investigated in 27 patients with primary hyperlipoproteinemias (hlp) (12 patients with hlp type IV, 7 patients with type IIb, 3 patients with type IIa, 4 patients with type V and 1 patient with type III)." | 3.66 | [Bezafibrate in primary hyperlipidemias (author's transl)]. ( Bode, G; Ditschuneit, H; Hutt, V; Klör, HU; Wechsler, JG, 1982) |
| "Pirozadil and alufibrate are compared by a single-blind study over two groups 20 patients with primary hyperlipoproteinemia." | 3.66 | [Single-blind study of the efficacy of pirozadil versus alufibrate in the treatment of primary hyperlipoproteinemias]. ( Azanza Perea, JR; Honorato Pérez, J, 1982) |
| "In a single-blind study the lipid-lowering drug gemfibrozil was compared at fixed dosage of 1600 mg daily with placebo and other drugs (mainly clofibrate) over a nine month period in 33 patients with hyperlipidaemia." | 2.65 | The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate. ( Nye, ER; Sutherland, WH; Temple, Wa, 1980) |
| "Twenty-two patients suffering from hyperlipidemia and receiving therapy consisting of a lipid-lowering diet and clofibrate (1 g X 2) were in addition given colestipol hydrochloride (5 g X 3) (Colestid, Upjohn) in a randomized, cross-over study for 2 periods of 6 weeks." | 2.65 | The effects of colestipol when combined with clofibrate in the treatment of severe hyperlipidemia. Short-term and long-term studies. ( Boberg, J; Hellsing, K; Lithell, H; Vessby, B, 1980) |
| "Both bezafibrate and EPL were tolerated well." | 2.65 | [Treatment of hyperlipoproteinaemia in diabetic patients (author's transl)]. ( Bruneder, H; Klein, HJ, 1981) |
| "Clofibrate has cholesterol- and triglyceride-lowering effect." | 2.39 | [Clofibrate treatment of hyperlipoproteinemia]. ( Midorikawa, H; Oikawa, S, 1994) |
| "Ciprofibrate is a phenoxyisobutyrate derivative with lipid-lowering effects in hyperlipoproteinaemia." | 1.27 | Effect of ciprofibrate treatment on biliary lipids in patients with hyperlipoproteinaemia. ( Angelin, B; Einarsson, K; Leijd, B, 1984) |
| "Eruptive and tubero-eruptive xanthomas arising at the site of previous minor skin injury are described in two patients with type IV and type III hyperlipidemia, respectively." | 1.27 | Eruptive and tubero-eruptive xanthomas of the skin arising on sites of prior injury. Two case reports. ( Davignon, J; Roederer, G; Xhignesse, M, 1988) |
| "Probucol has a sustained effect, additive to that of a lipid-lowering diet; it can reduce total serum cholesterol and cause xanthoma regression even in patients with receptor-defective homozygous familial hypercholesterolemia." | 1.27 | Medical management of hyperlipidemia and the role of probucol. ( Davignon, J, 1986) |
| "Ciprofibrate was convenient to take and was without subjective side effects." | 1.26 | Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia. ( Olsson, AG; Orö, L, 1982) |
| "Niceritrol treatment was associated with increased blood glucose, decreased K value, elevated fasting serum insulin and serum insulin at 60 min during IVGTT." | 1.26 | Changes in glucose tolerance and plasma insulin during lipid-lowering treatment with diet, clofibrate and niceritrol. ( Hellsing, K; Lithell, H; Vessby, B, 1982) |
| " The recommended dosage of clofibrate is 1." | 1.26 | [Fat and renal failure--therapeutic aspects]. ( Heidland, A; Hörl, M; Hörl, WH, 1982) |
| " In type IIa etofylline clofibrate shows a good effect on total cholesterol and on the cholesterol fractions, both with regard to the collective treated and to the low dosage of 750 mg/d etofylline clofibrate compared to the usual dosage of 1500 mg clofibrate." | 1.26 | [On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)]. ( Hausmann, L; Mühlfellner, G; Mühlfellner, O; Schneider, J; Schubotz, R, 1980) |
| "Clofibrate treatment resulted in a reduction of plasma cholesterol, hepatic HMG-CoA reductase and cholesterol 7 alpha-hydroxylase activities." | 1.26 | Effect of probucol on cholesterol metabolism in the rat. ( Holets, RJ; Kottke, BA; Li, JR, 1980) |
| "Niceritrol treatment significantly reduced the Chol/TG ratio in VLDL while no such effect was seen during clofibrate administration." | 1.26 | Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease. ( Borberg, J; Gustafsson, IB; Lithell, H; Vessby, B, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 73 (90.12) | 18.7374 |
| 1990's | 8 (9.88) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Keen, H | 1 |
| Lewis, B | 1 |
| Miller, NE | 1 |
| Wynn, V | 1 |
| Kaffarnik, H | 3 |
| Schneider, J | 4 |
| Schubotz, R | 3 |
| Zöfel, P | 2 |
| Hausmann, L | 2 |
| Goebel, KM | 1 |
| Donatelli, L | 1 |
| Walther, A | 1 |
| Mordasini, R | 1 |
| Riesen, W | 1 |
| Ratzmann, ML | 1 |
| Rjasanowski, I | 1 |
| Bruns, W | 1 |
| Ratzmann, KP | 1 |
| Słowińska, R | 1 |
| Bochenek, W | 1 |
| Unlot, J | 1 |
| Romics, L | 3 |
| Angelin, B | 2 |
| Einarsson, K | 2 |
| Leijd, B | 2 |
| Hanefeld, M | 2 |
| Hora, C | 1 |
| Schulze, J | 1 |
| Rothe, G | 1 |
| Barthel, U | 1 |
| Haller, H | 1 |
| Pados, G | 1 |
| Kusztos, D | 1 |
| Németh-Csóka, M | 1 |
| Valyon, M | 1 |
| Farkas, K | 1 |
| Hutt, V | 2 |
| Wechsler, JG | 2 |
| Klör, HU | 2 |
| Ditschuneit, H | 2 |
| Schatton, W | 2 |
| Schlierf, G | 1 |
| Fischer, H | 1 |
| Roche, A | 1 |
| Stiehl, A | 1 |
| Oster, P | 1 |
| Schellenberg, B | 1 |
| Vollmar, J | 2 |
| Gries, FA | 1 |
| Prager, R | 1 |
| Schernthaner, G | 1 |
| Kostner, GM | 1 |
| Mühlhauser, I | 1 |
| Zechner, R | 1 |
| Dorda, W | 1 |
| Reuter, W | 3 |
| Coffman, JD | 1 |
| Rasmussen, HM | 1 |
| Kemmer, C | 1 |
| Kadner, E | 1 |
| Nye, ER | 1 |
| Sutherland, WH | 1 |
| Temple, Wa | 1 |
| Olsson, AG | 1 |
| Orö, L | 1 |
| Machalke, K | 1 |
| Djaja, S | 1 |
| Richter, E | 1 |
| Pickering, JE | 1 |
| Lageder, H | 1 |
| Lithell, H | 3 |
| Vessby, B | 3 |
| Boberg, J | 1 |
| Hellsing, K | 2 |
| Tan, MH | 1 |
| Dick, TB | 1 |
| Marples, J | 1 |
| Ledermann, HM | 1 |
| Whittington, J | 1 |
| Fiegel, G | 1 |
| von Bock und Polach, U | 1 |
| Bode, G | 1 |
| Mertz, DP | 1 |
| Lang, PD | 1 |
| Heller, F | 1 |
| Honorato Pérez, J | 1 |
| Azanza Perea, JR | 1 |
| Hörl, WH | 1 |
| Hörl, M | 1 |
| Heidland, A | 1 |
| Mühlfellner, G | 2 |
| Mühlfellner, O | 1 |
| Vorberg, G | 1 |
| Ziegler, WJ | 1 |
| Padrón, RS | 1 |
| Amaro, S | 1 |
| Hung, S | 1 |
| Licea, M | 1 |
| Giorcelli, G | 1 |
| Vacha, G | 1 |
| Icardi, GP | 1 |
| Sale, JK | 1 |
| Johnstone, JH | 1 |
| Bruneder, H | 1 |
| Klein, HJ | 1 |
| Padosh, D | 1 |
| Kustosh, D | 1 |
| Puchok, I | 1 |
| Dem'ianova, N | 1 |
| Audikovski, M | 1 |
| Arteaga, A | 1 |
| Maiz, A | 1 |
| Lathrop, R | 1 |
| Szondy, E | 1 |
| Gerö, S | 1 |
| Weisweiler, P | 2 |
| Schwandt, P | 2 |
| Schwartzkopff, W | 2 |
| Schilling, A | 2 |
| Calder, D | 1 |
| Steger, W | 1 |
| Chevrel, B | 1 |
| Li, JR | 1 |
| Holets, RJ | 1 |
| Kottke, BA | 1 |
| Jarillo, MD | 1 |
| Coca, MC | 1 |
| Díaz Rubio, C | 1 |
| Bello, I | 1 |
| Gutiérrez-Millet, V | 1 |
| Ruilope, LM | 1 |
| Rodicio, JL | 1 |
| Alvarez Ude, F | 1 |
| Noseda, G | 1 |
| Fragiacomo, C | 1 |
| Weidmann, P | 1 |
| Bachmann, C | 1 |
| Ducobu, J | 1 |
| Oikawa, S | 1 |
| Midorikawa, H | 1 |
| Wilczek, H | 1 |
| Sobra, J | 3 |
| Ceska, R | 3 |
| Justová, V | 1 |
| Procházková, R | 2 |
| Kvasilová, M | 2 |
| Jůzová, Z | 1 |
| Toschnerová, H | 1 |
| Traurig, J | 1 |
| Fruchart, JC | 1 |
| Brewer, HB | 1 |
| Leitersdorf, E | 1 |
| Gustafsson, IB | 1 |
| Borberg, J | 1 |
| Neureuther, G | 1 |
| Bolzano, K | 1 |
| Krempler, F | 1 |
| Haslauer, F | 1 |
| Kollár, J | 1 |
| Rozdobud'ková, V | 1 |
| Koprovicová, J | 1 |
| Rajnová, E | 1 |
| Seiler, J | 1 |
| Kłosiewicz-Latoszek, L | 1 |
| Szostak, WB | 1 |
| Hunninghake, DB | 1 |
| Rywik, S | 1 |
| Roederer, G | 1 |
| Xhignesse, M | 1 |
| Davignon, J | 2 |
| Blum, CB | 1 |
| Levy, RI | 1 |
| Postiglione, A | 1 |
| Riccardi, G | 1 |
| Saldalamacchia, G | 1 |
| Stuyt, PM | 1 |
| Brown, WV | 1 |
| Holm, E | 1 |
| Parker, F | 1 |
8 reviews available for clofibrate and Hyperlipoproteinemia
| Article | Year |
|---|---|
[Pharmacology of probucol. I].
Topics: Adult; Aged; Animals; Anticholesteremic Agents; Chemical Phenomena; Chemistry; Cholesterol; Clofibra | 1984 |
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis.
Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperl | 1984 |
Drug treatment of hyperlipoproteinaemia.
Topics: Body Weight; Clofibrate; Gonadal Steroid Hormones; Humans; Hyperlipoproteinemias; Hypolipidemic Agen | 1983 |
HDL-cholesterol: the negative risk factor for coronary heart disease.
Topics: Adult; Age Factors; Alcoholism; Child; Cholesterol; Cholesterol, HDL; Cholestyramine Resin; Clofibra | 1980 |
[Clofibrate treatment of hyperlipoproteinemia].
Topics: Cholesterol; Clofibrate; Humans; Hyperlipoproteinemias; Lipoprotein Lipase; Lipoproteins; Liver; Tri | 1994 |
Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group.
Topics: Animals; Cholesterol, LDL; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hydroxymethylg | 1998 |
Drug treatment of dyslipoproteinemia.
Topics: Bile Acids and Salts; Clofibrate; Coronary Disease; Drug Therapy, Combination; Gemfibrozil; Humans; | 1990 |
[Basic principles of drug therapy of hyperlipoproteinemia].
Topics: Adult; Anticholesteremic Agents; Cholesterol; Clofibrate; Humans; Hyperlipoproteinemias; Hypolipidem | 1988 |
16 trials available for clofibrate and Hyperlipoproteinemia
| Article | Year |
|---|---|
[Study of the antilipemic effect of etofibrate (Lipo-Merz)].
Topics: Adult; Aged; Anticholesteremic Agents; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Female; | 1983 |
[Pharmacology and mechanism of action of etofibrate].
Topics: Animals; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Humans; Hyperlipoproteinemias; Hypoli | 1982 |
[The effect of bezafibrate on biliary lipids (author's transl)].
Topics: Adult; Bezafibrate; Bile; Clofibrate; Clofibric Acid; Drug Evaluation; Humans; Hyperlipoproteinemias | 1980 |
Effect of bezafibrate on plasma lipids, lipoproteins, apolipoproteins AI, AII and B and LCAT activity in hyperlipidemic, non-insulin-dependent diabetics.
Topics: Aged; Apolipoprotein A-II; Apolipoproteins; Apolipoproteins A; Apolipoproteins B; Bezafibrate; Chole | 1982 |
The peripheral circulation and treatment of hyperlipoproteinemias.
Topics: Adult; Aged; Arteriosclerosis Obliterans; Blood Circulation; Clofibrate; Colestipol; Female; Humans; | 1983 |
The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate.
Topics: Adult; Aged; Cholesterol; Clofibrate; Female; Gemfibrozil; Humans; Hyperlipoproteinemias; Lipoprotei | 1980 |
[Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias].
Topics: Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Clofibrate; Clofibr | 1982 |
[Comparative double-blind investigation of bezafibrate and clofibrate in patients with primary hyperlipoproteinaemia].
Topics: Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemias; Male; P | 1980 |
The effects of colestipol when combined with clofibrate in the treatment of severe hyperlipidemia. Short-term and long-term studies.
Topics: Alkaline Phosphatase; Cholesterol; Clofibrate; Colestipol; Drug Therapy, Combination; Female; Humans | 1980 |
Comparative study of once and 3-times daily regimens of bezafibrate in patients with primary hyperlipoproteinaemia.
Topics: Adult; Aged; Alkaline Phosphatase; Bezafibrate; Cholesterol; Clinical Trials as Topic; Clofibrate; C | 1981 |
[Therapeutic effect of etofyllinclofibrate in disordered lipid and uric acid metabolism].
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Clofibrate; Female; Humans; Hy | 1982 |
[Therapeutic experiences in the treatment of hyperlipoproteinaemia with etofylline clofibrate (author's transl)].
Topics: Clofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia | 1980 |
[Treatment of hyperlipoproteinaemia in diabetic patients (author's transl)].
Topics: Adult; Aged; Bezafibrate; Blood Glucose; Cholesterol; Clofibrate; Clofibric Acid; Diabetes Complicat | 1981 |
[Therapy of lipoproteinemia. Comparison between Lipo-Merz retard and a commercial combination drug].
Topics: Adult; Aged; Cholesterol; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Drug Combinations | 1980 |
[Is hypolipemic treatment effective as a preventive measure?].
Topics: Adult; Arteriosclerosis; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Clofibrat | 1989 |
Hypolipidemic effects of bezafibrate: studies in Italy.
Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Double-Blind Method; Humans; Hyperlipoproteinemia | 1986 |
57 other studies available for clofibrate and Hyperlipoproteinemia
| Article | Year |
|---|---|
Clofibrate and hyperlipidaemia.
Topics: Clofibrate; Diabetic Retinopathy; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Ty | 1980 |
Long-term treatment of hyperlipoproteinemia with etofibrate: clinical observations.
Topics: Adult; Aged; Cholesterol; Clofibrate; Clofibric Acid; Creatine Kinase; Female; gamma-Glutamyltransfe | 1980 |
[Changes in serum lipoproteins in kidney diseases. Therapeutic possibilities].
Topics: Clofibrate; Dietary Fats; Energy Metabolism; Humans; Hyperlipoproteinemias; Kidney Failure, Chronic; | 1983 |
Effects of clofibrate therapy on glucose tolerance, insulin secretion and serum lipids in subjects with hyperlipoproteinemia and impaired glucose tolerance. A follow-up study over a five-year period.
Topics: Adult; Blood Glucose; Cholesterol; Clofibrate; Follow-Up Studies; Glucose Tolerance Test; Humans; Hy | 1983 |
Effect of ciprofibrate treatment on biliary lipids in patients with hyperlipoproteinaemia.
Topics: Adult; Aged; Bile; Bile Acids and Salts; Cholesterol; Clofibrate; Clofibric Acid; Female; Fibric Aci | 1984 |
Reduced incidence of cardiovascular complications and mortality in hyperlipoproteinemia (HLP) with effective lipid correction. The Dresden HLP study.
Topics: Adolescent; Adult; Cerebrovascular Disorders; Cholesterol; Cholestyramine Resin; Clofibrate; Combine | 1984 |
Favourable effect of combined Miscleron-Xavin treatment on HDL-cholesterol level.
Topics: Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Drug Therapy, Combination; Humans; Hyperlipoproteine | 1983 |
Consensus conference: Treatment of hypertriglyceridemia.
Topics: Body Weight; Cardiovascular Diseases; Clofibrate; Gemfibrozil; Humans; Hyperlipidemias; Hyperlipopro | 1984 |
[Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
Topics: Clofibrate; Drug Combinations; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; H | 1983 |
[Longterm therapy and etofibrate (author's transl)].
Topics: Anticholesteremic Agents; Blood Cell Count; Blood Glucose; Clofibrate; Clofibric Acid; Drug Administ | 1980 |
[Drug therapy of hypertriglyceridemias (author's transl)].
Topics: Clofibrate; Humans; Hyperlipoproteinemias; Nicotinic Acids; Triglycerides | 1980 |
Clofibrate treatment and bile cholesterol saturation: short-term and long-term effects and influence of combination with chenodeoxycholic acid.
Topics: Adult; Aged; Bile; Chenodeoxycholic Acid; Cholesterol; Clofibrate; Drug Therapy, Combination; Female | 1981 |
[Effect of combination therapy of clofibric acid and nicotinic acid derivatives on fatty acid metabolism in hyperlipoproteinemia].
Topics: Aged; Clofibrate; Clofibric Acid; Drug Therapy, Combination; Fatty Acids; Female; Humans; Hyperlipop | 1982 |
Relationship between morphological changes and lipid-lowering action of p-chlorphenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man.
Topics: Adult; Aged; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemias; Male; Microbodies; M | 1983 |
Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Blood Sedimentation; Body Weight; Cholesterol; Ch | 1982 |
Nutritional & pharmacologic management of hyperlipoproteinemia.
Topics: Cholesterol; Cholesterol, Dietary; Clofibrate; Dietary Fats; Gemfibrozil; Humans; Hyperlipoproteinem | 1982 |
Changes in glucose tolerance and plasma insulin during lipid-lowering treatment with diet, clofibrate and niceritrol.
Topics: Aged; Arteriosclerosis; Blood Glucose; Body Weight; Clofibrate; Dietary Carbohydrates; Female; Gluco | 1982 |
[Lowering lipids rapidly and permanently with etofibrate].
Topics: Cholestyramine Resin; Clofibrate; Clofibric Acid; Dextrothyroxine; Humans; Hyperlipoproteinemias; Li | 1982 |
[Bezafibrate in primary hyperlipidemias (author's transl)].
Topics: Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Clofibric Acid; Female; Hu | 1982 |
Bezafibrate: lack of effect on creatinine excretion and muscular proteins.
Topics: Bezafibrate; Clofibrate; Clofibric Acid; Creatine Kinase; Creatinine; Female; Humans; Hyperlipoprote | 1982 |
[Clofibrate therapy--the status quo].
Topics: Carcinogens; Cholelithiasis; Cholesterol; Clofibrate; Humans; Hyperlipoproteinemias; Lipoproteins, L | 1982 |
[Should clofibrate still be prescribed?].
Topics: Adult; Animals; Cardiovascular Diseases; Cholesterol; Clofibrate; Cricetinae; Humans; Hyperlipoprote | 1982 |
[Single-blind study of the efficacy of pirozadil versus alufibrate in the treatment of primary hyperlipoproteinemias].
Topics: Cholesterol; Clofibrate; Clofibric Acid; Drug Evaluation; Female; Humans; Hyperlipoproteinemias; Lip | 1982 |
[Fat and renal failure--therapeutic aspects].
Topics: Acute Kidney Injury; Animals; Bezafibrate; Carnitine; Charcoal; Clofibrate; Clofibric Acid; Humans; | 1982 |
[Current treatment with clofibrate or clofibric acid (Regadrin)].
Topics: Cholelithiasis; Cholesterol; Clofibrate; Clofibric Acid; Humans; Hypercholesterolemia; Hyperlipoprot | 1982 |
[What is important in therapy of hyperlipoproteinemia. Lipo-Merz retard (etofibrate) lowers the atherogenic index].
Topics: Anticholesteremic Agents; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Humans; Hyperlipo | 1982 |
[On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)].
Topics: Cholesterol; Clofibrate; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipids; Lipoproteins; | 1980 |
[Association of vasopressin-sensitive diabetes insipidus with hyperlipoproteinemia].
Topics: Adolescent; Adult; Clofibrate; Diabetes Insipidus; Female; Humans; Hyperlipoproteinemias; Male; Midd | 1981 |
Drug treatment of hypertriglyceridaemia in chronic uraemic patients: preliminary report on D,L-carnitine and thiadenol.
Topics: Carnitine; Chronic Disease; Clofibrate; Fatty Alcohols; Humans; Hyperlipoproteinemias; Lipid Metabol | 1980 |
Pre- and post-treatment values of HDL cholesterol and total: HDL cholesterol ratio in hyperlipoproteinaemic subjects.
Topics: Cholesterol; Cholesterol, HDL; Clofibrate; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipopr | 1981 |
[Effect of diet and drug therapy on the level of high density lipoprotein cholesterol in patients with primary hyperlipoproteinemia].
Topics: Biguanides; Cholesterol; Cholesterol, HDL; Clofibrate; Dietary Fats; Humans; Hyperlipoproteinemias; | 1981 |
[Hyperlipoproteinemias: experience of out-patient treatment of 112 patients (author's transl)].
Topics: Body Weight; Cholesterol; Cholestyramine Resin; Clofibrate; Humans; Hyperlipoproteinemias; Hypolipid | 1981 |
[Effect of clofibrate therapy on serum lipids and lipoproteins].
Topics: Clofibrate; Humans; Hyperlipoproteinemias; Lipids; Lipoproteins; Male; Middle Aged | 1980 |
[Lipoproteins and hyperlipoproteinemias].
Topics: Blood Protein Disorders; Cholesterol; Cholestyramine Resin; Clofibrate; Diet Therapy; Humans; Hyperl | 1980 |
[Therapy of hyperlipoproteinemia type IIa, IIb and IV with Etofibrate retard].
Topics: Blood Glucose; Cholesterol; Clofibrate; Creatinine; Delayed-Action Preparations; Humans; Hyperlipopr | 1980 |
[Chenodeoxycholic acid. Indications in biliary pathology and hyperlipoproteinemias].
Topics: Bile Duct Diseases; Chenodeoxycholic Acid; Cholelithiasis; Cholesterol; Clofibrate; Dilatation, Path | 1980 |
Effect of probucol on cholesterol metabolism in the rat.
Topics: Animals; Body Weight; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Clofibrate; Hydroxymethylglutary | 1980 |
[Low dose clofibrate in the treatment of hypertriglyceridemia in hemodialysis patients (author's transl)].
Topics: Adolescent; Adult; Clofibrate; Female; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Kidney F | 1980 |
[The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
Topics: Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Humans; Hyperlipoproteinemia Type II; Hyperlip | 1980 |
Creatinekinase in hyperlipoproteinemic patients treated with clofibrate.
Topics: Clofibrate; Creatine Kinase; Female; Humans; Hyperlipoproteinemias; Male; Middle Aged; Muscular Dise | 1980 |
[Comparative research on etofibrate retard and fenofibrate in hyperlipoproteinemia].
Topics: Aged; Cholesterol; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Female; Fenofibrate; Hum | 1980 |
[Physiopathology of hyperlipidemias, practical approach (author's transl)].
Topics: Adult; Clofibrate; Diet Therapy; Humans; Hyperlipoproteinemias; Lipoproteins; Middle Aged | 1980 |
[Therapy with fibrates and vitamin D metabolism].
Topics: Adult; Clofibrate; Female; Fenofibrate; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Male; M | 1993 |
[Duolip Forte--experience during a 6-month period of administration].
Topics: Adult; Aged; Clofibrate; Female; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle A | 1993 |
Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease.
Topics: Adult; Aged; Arteriosclerosis; Clofibrate; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipopr | 1979 |
Serum lipoprotein lipids after gemfibrozil treatment.
Topics: Adult; Aged; Cholesterol; Clofibrate; Humans; Hyperlipoproteinemias; Lipoproteins; Lipoproteins, HDL | 1979 |
[Treatment of various types of hyperlipoproteinaemia with a combination of Mg-chlorophenoxy-isobutyrate and mesoinositol-hexanicotinate (author's transl)].
Topics: Adult; Aged; Cholesterol; Clofibrate; Clofibric Acid; Drug Combinations; Female; Humans; Hyperlipopr | 1979 |
[Is Etolip suitable for treatment of various types of hyperlipoproteinemias?].
Topics: Adult; Clofibrate; Humans; Hyperlipoproteinemias; Lipids; Middle Aged | 1991 |
Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Colestipol; Female; Fenofibrate; | 1991 |
[Etolip and Lipanthyl in the treatment of hyperlipoproteinemia].
Topics: Clofibrate; Female; Fenofibrate; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle A | 1990 |
Eruptive and tubero-eruptive xanthomas of the skin arising on sites of prior injury. Two case reports.
Topics: Adult; Clofibrate; Female; Gemfibrozil; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Male; M | 1988 |
Medical management of hyperlipidemia and the role of probucol.
Topics: Adult; Arteriosclerosis; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Female; Gem | 1986 |
Rational drug therapy of the hyperlipoproteinemias, Part II.
Topics: Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyroxine; Female; Fish Oils; Gemfibrozil; Human | 1986 |
[Drugs in hyperlipidemia].
Topics: Cholestyramine Resin; Clofibrate; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemi | 1987 |
Potential use of fenofibrate and other fibric acid derivatives in the clinic.
Topics: Clofibrate; Fenofibrate; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hy | 1987 |
[Etofibrate in severe diet-refractory cases of hyperlipoproteinemia].
Topics: Adult; Aged; Cholesterol; Clofibrate; Clofibric Acid; Dietary Fats; Female; Humans; Hyperlipoprotein | 1986 |
Xanthomas and hyperlipidemias.
Topics: Apoproteins; Arteriosclerosis; Cholestasis; Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyr | 1985 |